Background
==========

Artemisinin-based combination therapy (ACT) has been adopted as first-line treatment for *Plasmodium falciparum* malaria in virtually all malaria-endemic countries. In the view of spreading anti-malarial drug resistance and the emergence of the first cases of compromised susceptibility to artemisinins along the Thai-Cambodian border the development of novel compounds and combinations for the treatment of falciparum malaria has become an issue of utmost importance \[[@B1],[@B2]\]. First studies conducted in 1969 and 1970 in rhesus monkeys infected with *Plasmodium cynomolgi*, a malaria parasite of monkeys similar to *Plasmodium vivax,* have shown that mirincamycin, a synthetically-produced lincosamide antibiotic similar to clindamycin, has substantial antiplasmodial activity for prophylaxis as well as for radical cure in animal models \[[@B3],[@B4]\]. Moreover in the above-mentioned *P. cynomolgi* model mirincamycin was shown to be superior compared to clindamycin in both, prophylaxis and radical cure. In 1985 Schmidt *et al.* showed that concomitant administration of mirincamycin improved the hypnozoitocidal efficacy of primaquine in a *P. cynomolgi* model suggesting that the primaquine dose required for radical cure could be reduced by one-half to two-thirds by coadministration with mirincamycin \[[@B5]\]. In 2010, Held *et al.*\[[@B6]\] assessed the *in vitro* activity of mirincamycin in *P. falciparum* field isolates from Gabon and indicated that mirincamycin is more active than the comparator drugs clindamycin and doxycycline. In Gabon, the observed mean IC~50~ measure after six days of incubation was 10,000-fold lower than on day 3, suggesting a slow onset of action (delayed death phenomenon) as previously described for several other antibiotics \[[@B6]-[@B8]\]. A recent study by Khemawoot *et al.* found a more than 100-fold increased potency against field isolates of *P. falciparum* cultured *ex vivo* in primate plasma compared to *in vitro* investigations with the W2 clone \[[@B9]\]. A challenge for the radical cure of *P. vivax* remains the haemolytic toxicity of primaquine in G6PD-deficient individuals. Earlier studies suggest that mirincamycin may improve the efficacy of 8-aminoquinolines, thereby potentially allowing for lower doses and reducing toxicity when given in combination \[[@B5]\].

Therefore, mirincamycin has been investigated as a promising combination partner for prophylaxis and treatment of falciparum malaria.

Methods
=======

Study area
----------

The study was carried out at the MARIB (Malaria Research Initiative Bandarban) field site in Bandarban in southeastern Bangladesh and at the laboratories of the Medical University of Vienna, Austria.

Ethics
------

Written informed consent was obtained from all study participants or their legal representatives and the study protocol was approved by the Ethical Review Committees of the ICDDR,B and the Medical University of Vienna.

Sampling
--------

Blood samples were taken from male and non-pregnant female patients aged 8 to 65 years, presenting with microscopically confirmed *P. falciparum* monoinfections and parasite densities between 1,000 and 100,000 asexual parasites per μl. Blood samples exceeding 1% parasitemia were diluted with uninfected red blood cells before testing. Pregnant or breastfeeding women and patients with anti-malarial drug therapy in the preceding 30 days were excluded from participation.

Drug susceptibility testing
---------------------------

Mirincamycin (4'-trans-mirincamycin hydrochloride, molecular weight \[MW\] 475.47) was provided by Richard Westerman (Maldevco), tafenoquine (MW 463.49) by GlaxoSmithKline (GSK), clindamycin hydrochloride (MW 461.44), azithromycin (MW 748.98), dihydroartemisinin (MW 284.3), chloroquine diphosphate (MW 515.90), quinine sulphate (MW 782.96) and mefloquine hydrochloride (MW 414.77) were obtained from Sigma Aldrich. All drugs were dissolved in 70% ethanol to obtain a 1 mg/ml stock solution.

All samples were cultured for 72 hours to allow for a direct comparison among all test substances and combinations and growth inhibition assessed using the histidine-rich-protein 2 (HRP2) *in vitro* drug susceptibility assay. The culture and enzyme linked immunosorbent assay (ELISA) were performed as previous described \[[@B8],[@B10],[@B11]\].

To investigate interaction profiles and most effective ratio of concentrations of mirincamycin in combination with standard anti-malarials, fresh *P. falciparum* field isolates and culture-adapted *P. falciparum* clones K1 (chloroquine-resistant) and 3D7 (chloroquine-sensitive) were tested in checkerboard assays and data analysis was done as previously described \[[@B11]-[@B13]\]. Checkerboards assessing optimum concentrations of various drugs in combination were performed by diluting trans-mirincamycin (MIR 27.43 to 20,000 ng/ml) vertically and either chloroquine (CQ 3.43 to 2,500 ng/ml), tafenoquine (TQ 34.29 to 25,000 ng/ml) or dihydroartemisinin (DHA 0.02 -- 15 ng/ml) horizontally in a three-fold serial dilution using a standard 8x8 well design on microtiter plates.

In addition single compounds were testes with fresh *P. falciparum* field isolates in the presence of three-fold serial dilutions of the anti-malarial drugs *trans*-mirincamycin (MIR; 137.2 to 100,000 ng/ml), clindamycin (CLM; 68.6 to 50,000 ng/ml), azithromycin (AZM; 68.6 to 50,000 ng/ml), dihydroartemisinin (DHA; 0.034 to 25.0 ng/ml), chloroquine (CHL; 3.4 to 2,500 ng/ml), quinine (QNN; 3.4 to 2,500 ng/ml) and mefloquine (MEF; 0.3 to 250 ng/ml) and subsequently growth inhibition was quantified in a HRP2 ELISA. In a subset of samples *trans*-mirincamycin and clindamycin were also tested after 24 h incubation using the WHO microtest \[[@B14]\].

Data analysis
-------------

The 50 and 90% inhibitory concentrations (IC~50s~ and IC~90s~, respectively) were calculated from optical density readings by nonlinear regression analysis. ICs were used to calculate fractional inhibitory concentrations (FICs) as previously described \[[@B11],[@B13]\]. Isobolograms were plotted to demonstrate synergism (FIC \< 0.5) and/or antagonism (FIC \> 2) for drug combinations. Activity correlations were calculated by nonparametric correlation analysis (Spearman).

Results
=======

Results of mirincamycin in combination with DHA, CQ and TQ are shown in Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}. All combinations with mirincamycin were additive with a slight trend to synergism, with an overall geometric mean fractional inhibitory concentration at 50% inhibition (FIC~50~) of 0.78, 0.80 and 0.80 for TQ, DHA, and CQ, respectively. Antagonism was not detected for any of the tested field isolates or clones. The highest level of synergism (i.e. the lowest FICs) was found for the combination of tafenoquine with mirincamycin at a ratio of 1:0.27 to 1:7.2 (mean 1:2.7). The optimal combination ratios were 1:444.4 to 1:36,000 (mean 1:10,755.5) and 1:2.7 to 1:216 (mean 1:64.5) for DHA and CQ, respectively.

###### 

Results of mirincamycin in combination with DHA, CQ and TQ

                                            **IC**~**50**~**(nM)**   **IC**~**90**~**(nM)**   **ΣFIC**~**50**~^**a**^   **ΣFIC**~**90**~^**a**^         
  ---------------------------------------- ------------------------ ------------------------ ------------------------- ------------------------- ------ ------
  Field isolates (n^b^ = 3)                        2,962.85                 2,357.12                 9,027.36                  15,653.18          0.56   0.50
  3D7 (n^c^ = 3)                                   1,348.48                19,539.36                  2728.49                  36,936.11          0.86   1.09
  K1 (n^c^ = 2)                                    1,076.23                24,736.61                 5,271.96                  39,284.24          0.88   1.03
  All tested isolates (n = 8)                      1,829.64                 8,135.69                 5,005.97                  25,786.65          0.78   0.83
  **DHA -- mirincamycin** (n)                        DHA                      MIR                       DHA                       MIR                      
  Field isolates (n^b^ = 4)                          3.23                   1,067.34                   13.0                    20,101.72          0.81   0.69
  3D7 (n^c^ = 3)                                     1.90                  16,995.36                   4.78                    34,781.20          0.86   0.85
  K1 (n^c^ = 2)                                      1.09                   8,669.49                   2.86                    27,749.81          0.71   0.95
  All tested isolates (n = 9)                        2.12                   4,276.94                   6.65                    25,925.12          0.80   0.83
  **Chloroquine -- mirincamycin** (n^b^)             CHL                      MIR                       CHL                       MIR                      
  Field isolates (n^b^ = 2)                         128.99                  1,365.01                  680.90                   16,161.82          0.39   0.99
  3D7 (n^c^ = 4)                                    28.27                  23,288.21                   63.87                   38,311.62          1,06   1.04
  K1 (n^c^ = 2)                                     651.93                 18,869.50                 1,174.69                  36,535.66          0.95   0.99
  All tested isolates (n = 8)                       90.54                  10,871.57                  239.01                   30,511.74          0.80   0.91

^a^Synergy, \<0.5; additivity, 0.5-2; antagonism,\>2.

^b^n, no. of fresh field isolates tested.

^c^n, no. of repeats.

Geometric mean IC~50~ and IC~90~ in nM for mirincamycin (MIR), tafenoquine (TQ), chloroquine (CHL) and dihydroartemisinin (DHA) as well as the sum of fractional inhibitory (ΣFIC) concentrations for *P. falciparum* field isolates and culture clones 3D7 (chloroquine-sensitive) and K1 (chloroquine-resistant) tested in checkerboards assays.

![**Isobolograms of mirincamycin in combination with tafenoquine, dihydroartemisinin and chloroquine.** Isobolograms for the checkerboards assays of mirincamycin in combination with tafenoquine, dihydroartemisinin and chloroquine at various concentration ratios for all successfully tested isolates at FIC~50~ level. All individual data points (pooled FIC~50~s) at various concentration ratios are presented on the left hand side, isobolograms on the right side point out the geometric mean of the individual data points. The straight lines in each panel are representing the type of interaction. Data points below the 0.5-line show synergism (FIC \< 0.5), around the 1.0-line are additive (FIC 0.5-2) and above the 2-line are antagonistic (FIC \> 2).](1475-2875-13-228-1){#F1}

Out of a total of 55 patient samples 43 (78.2%; 95% confidence interval \[CI\]: 64.6 to 87.8) were successfully tested with a geometric mean parasite density of 7,646 per μL (95% CI: 5,399 to 10,827). The geometric mean of the 50% inhibitory concentration (IC~50~) for *trans*-mirincamycin was 1,212.6 nM (N = 43; 95% CI: 703.9 to 2,088.9) and the corresponding value for clindamycin was 880.4 nM (N = 43; 95% CI: 469.7 to 1,650.1). IC~50~, IC~90~, IC~99~ values with 95% confidence intervals for all drugs tested are shown in Table [2](#T2){ref-type="table"}. No correlation was found between parasite density and inhibitory concentrations (IC~50~) of mirincamycin (R = 0.14; P = 0.4) and clindamycin (R = 0.10; P = 0.5) suggesting little influence of the inoculum size on the validity of *in vitro* assays. Individual IC values were calculated for all drugs tested in parallel and compared by nonparametric correlation analysis to determine potential cross-sensitivity and/or cross-resistance patterns between the drugs. Mirincamycin showed significant activity correlation with clindamycin (R = 0.64; P = 0.0002; N = 28) and azithromycin (R = 0.390; P = 0.040; N = 28) but no evidence of a correlation with any of the other tested anti-malarials (dihydroartemisinin: R = 0.269; P = 0.166; N = 28, mefloquine: R = 0.031; P = 0.875; N = 28, quinine: R = 0.025; P = 0.901; N = 28 and chloroquine: R = 0.319; P = 0.098; N = 28).

###### 

**Geometric mean inhibitory concentration of various drugs against fresh*P. falciparum*isolates from Bangladesh**

  **Antiplasmodial activity \[nm\] (95% CI)**                                                                  
  --------------------------------------------- ---------------------------- --------------------------------- ---------------------------------
  MIR (n = 43)                                  1,212.6 (703.9 -- 2088.9)    12,116.4 (6296.4 -- 23 316.0)     34,329.2 (18 895.1 -- 62 370.2)
  CLI (n = 43)                                  880.4 (469.7 -- 1650.1)      12,074.7 (6470.9 -- 22 531.2)     36,581.3 (24 386.7 -- 54 873.9)
  AZM (n = 43)                                  4,082.6 (2947.5 -- 5654.8)   21,781.4 (17 004.1 -- 27 901.0)   39,979.5 (26 901.2 -- 59 415.9)
  DHA (n = 42)                                  0.9 (0.7 -- 1.1)             2.9 (2.2 -- 4.0)                  4.8 (3.3 -- 6.9)
  CHL (n = 42)                                  102.6 (78.0 --134.9)         370.6 (279.1 -- 492.1)            651.2 (467.1 -- 907.9)
  QNN (n = 42)                                  61.2 (46.6 -- 80.2)          289.4 (236.2 -- 354.7)            538.5 (421.2 -- 688.5)
  MEF (n = 42)                                  13.6 (9.3 -- 20.0)           64.9 (47.1 -- 89.3)               272.7 (38.1 -- 1953.9)

^a^n, no. of fresh field isolates tested.

^b^MIR, mirincamycin; CLI, clindamycin; AZM, azithromycin; DHA, dihydroartemisinin; CHL, chloroquine; QNN, quinine; MEF, mefloquine.

IC~50~s for trans-mirincamycin and clindamycin were 111 and 79 times higher after only 24 h incubation than after 72 h incubation, suggesting a slow mode of action in malaria parasites.

Discussion
==========

So far there is only limited evidence for the *in vitro*\[[@B6]\] and *ex vivo* activity \[[@B9]\] of mirincamycin. *P. cynomolgi* animal models have proven that mirincamycin was curative even when given as monotherapy \[[@B3],[@B4]\]. Interestingly, the substance seems to show considerable activity against hypnozoites \[[@B4]\], and may enhance the effect of primaquine when given in combination \[[@B5]\].

For the first time, these results prove that mirincamycin has an additive mode of interaction *in vitro* with a slight trend to synergism when combined with various standard anti-malarials. Similar drug interaction profiles were found 2003 by Ramharter *et al.* for clindamycin in combination with DHA where effective concentrations of clindamycin were comparable to our results for mirincamycin \[[@B15]\]. Subsequently conducted clinical trials have proven high efficacy of clindamycin in combination with conventional anti-malarial drugs \[[@B16]\]. Clinical studies will need to show in how far this is also the case for mirincamycin.

8-aminoquinolines (like primaquine and tafenoquine) can cause severe haemolysis in individuals with G6PD deficiency. The challenge is therefore either to improve the efficacy and thereby potentially reduce the dose of 8-aminoquinolines with new combination partners possibly resulting in a reduced risk of haemolysis or to overcome this side effect with safer replacement drugs.

Mirincamycin alone or in combination (e.g. with 8-aminoquinolines) may be a promising candidate for malaria prophylaxis in nonimmune subjects, such as tourists and soldiers and could potentially help to enhance the hypnozoitocidal activity of 8-aminoquinolines by concomitant administrion, as previously demonstarted in a *P. cynomolgi* model \[[@B4],[@B5]\]. A lower dose could potentially also result in improved safety of 8-aminoquinolines (e.g. in glucose-6-phosphatedehydrogenase-deficient subjects).

Limitations of this study include all potential shortcomings of an *in vitro* study as well as the potential bias arising from the fact that only *P. falciparum* has been tested which cannot be extrapolated to *P. vivax* or *P. ovale* in the absence of a well-established culture model \[[@B17]\]. Also among 8-aminoquinolines only tafenoquine was tested in this study, which in recent studies has demonstrated high efficacy in the treatment and relapse prevention of vivax malaria in combination with chloroquine \[[@B18]\]. However, currently primaquine remains the only 8-aminoquinolone widely used for *P. vivax* radical cure.

Conclusions
===========

The study showed that mirincamycin has additive to synergistic interaction in combination with different classes of anti-malarials, exhibits no activity correlation with traditional anti-malarials and exerts substantial anti-malarial activity on its own. As a consequence mirincamycin may be a potential candidate for clinical exploration either in combination with faster acting anti-malarials in the treatment of multidrug-resistant falciparum malaria or in combination with other drugs for the treatment of non-falciparum malaria.
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